actinium ac 225-dota-anti-steap2 monoclonal antibody azd2284
Generic: Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284
actinium ac 225-dota-anti-steap2 monoclonal antibody azd2284: 1 clinical trial tracked.
actinium ac 225-dota-anti-steap2 monoclonal antibody azd2284 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about actinium ac 225-dota-anti-steap2 monoclonal antibody azd2284, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trials (1)
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Number of participants with adverse event (AEs)
Interventionalopen95 targetStarted 2025-03Completion 2029-0415 sites · Australia, South Africa, United StatesAstraZeneca